TR
$4.73
+0.08
(+1.72%)
As of Oct 22, 2026, 9:29 PM EDT · cached
Price history
Entrada Therapeutics Inc (TRDA) is trading up at $4.73 (+1.72%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: October 29, 2021 · $20.00 offering · NASDAQ · View IPO details →
Entrada Therapeutics Inc revenue & net income history (FY2020–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | $129.0M | $210.8M | $25.4M |
| Growth (year over year) | — | — | — | — | +63.4% | −87.9% |
| Operating income | −$26.7M | −$51.1M | −$97.2M | −$3.16M | $47.0M | −$157.9M |
| Operating margin | — | — | — | −2.5% | 22.3% | −621.1% |
| Net income | −$26.5M | −$51.2M | −$94.6M | −$6.68M | $65.6M | −$143.8M |
| Net margin | — | — | — | −5.2% | 31.1% | −565.5% |
| EPS (diluted) | −$24.00 | −$8.16 | −$3.02 | −$0.20 | $1.68 | −$3.47 |
| Balance sheet | ||||||
| Cash and equivalents | $39.0M | $291.1M | $45.2M | $67.6M | $101.2M | $90.4M |
| Total assets | $43.5M | $305.8M | $252.1M | $469.2M | $526.3M | $377.4M |
| Total liabilities | $3.36M | $7.12M | $39.5M | $226.8M | $97.6M | $71.2M |
| Shareholders' equity | −$41.5M | $298.7M | $212.6M | $242.4M | $428.7M | $306.1M |
| Cash flow | ||||||
| Operating cash flow | −$25.6M | −$50.9M | −$93.8M | $139.8M | −$41.6M | −$128.5M |
| Capital expenditure | $2.32M | $4.58M | $2.89M | $5.61M | $3.16M | $1.04M |
| Free cash flow | −$27.9M | −$55.4M | −$96.7M | $134.2M | −$44.7M | −$129.6M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.6M | $37.4M | $20.6M | $1.95M | $1.61M | — | $875.0K | $898.0K |
| Growth (year over year) | −55.3% | −10.6% | −65.2% | −97.9% | −91.8% | — | −95.7% | −53.9% |
| Operating income | −$21.7M | −$5.87M | −$21.8M | −$46.8M | −$47.1M | — | −$42.3M | −$45.0M |
| Operating margin | −110.7% | −15.7% | −106.0% | −2402.5% | −2915.2% | — | −4834.6% | −5007.0% |
| Net income | −$14.0M | $1.13M | −$17.3M | −$43.1M | −$44.1M | — | −$39.7M | −$42.8M |
| Net margin | −71.7% | 3.0% | −84.4% | −2210.4% | −2734.4% | — | −4539.1% | −4762.0% |
| EPS (diluted) | −$0.35 | −$0.20 | −$0.42 | −$1.04 | −$1.06 | — | −$0.95 | −$1.01 |
| Balance sheet | ||||||||
| Cash and equivalents | $78.0M | $101.2M | $67.8M | $72.5M | $93.3M | $90.4M | $76.4M | $99.3M |
| Total assets | $554.6M | $526.3M | $486.5M | $448.8M | $412.9M | $377.4M | $335.5M | $298.9M |
| Total liabilities | $132.1M | $97.6M | $69.2M | $69.3M | $72.2M | $71.2M | $64.7M | $65.5M |
| Shareholders' equity | $422.4M | $428.7M | $417.3M | $379.5M | $340.7M | $306.1M | $270.9M | $233.4M |
| Cash flow | ||||||||
| Operating cash flow | −$24.3M | −$31.6M | −$38.5M | −$29.5M | −$28.3M | — | −$41.7M | −$32.5M |
| Capital expenditure | $639.0K | $635.0K | $1.14M | $275.0K | −$171.0K | — | $44.0K | $11.0K |
| Free cash flow | −$24.9M | −$32.2M | −$39.7M | −$29.8M | −$28.1M | — | −$41.7M | −$32.5M |
From Entrada Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Entrada Therapeutics Inc
- Headquarters
- Boston, Massachusetts From SEC filings, Oct 2026
Recent News (3)
-
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer Entrada Therapeutics announces the appointment of Linea Aspesi as Chief People Officer.
-
-
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study Entrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 study.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International